Skip to content

Supreme Court Hears Plea on Drug Prices; Doctor Demands Reform

By News Analysis India · · 3 min read

New Delhi, October 27: During a hearing on a petition challenging the exorbitant prices of medicines, the Supreme Court raised a key question about the role of pharmaceutical companies. The court asked whether firms are only running a business or are also considering public interest and the usefulness of their products. It said that earning profit is acceptable, but disproportionate profiteering is not.

The petitioner, Dr Sanjay Kulshreshtha, told reporters that he had presented real patient bills before the court. According to him, these bills showed that some drugs were being sold at 10 to 15 times higher than expected.

Describing the proceedings, Dr Kulshreshtha said the court had been clear in its remarks. It had asked whether the petitioners were focused only on business or were also considering public interest and utility. He said the court already had these concerns in mind and had commented on the petition earlier. He added that during arguments by senior advocates, including Kapil Sibal, the court observed that most points raised in the petitions of Dr Rathore and Dr Kulshreshtha were clear.

He said that as doctors who perform surgeries, they had shown in patient bills that several medicines were being charged at 10 to 15 times the price. The court, he said, accepted these facts during the hearing. The petitioners had filed a written representation and a rejoinder, and had responded to the arguments put forward by the Ministry of Chemicals and Fertilizers.

He argued that the scope of the case should not be limited to cancer drugs. All medicines should be covered, he said, because the most sold drugs in India include those for heart disease, diabetes, acidity, pain relief and antibiotics. Most of these, he noted, have nothing to do with cancer.

Dr Kulshreshtha also said there should be no separate treatment for essential and non-essential medicines. For a patient, any medicine a doctor prescribes is important, and any drug that saves a life matters regardless of its classification.

He explained that the World Health Organization originally developed the essential medicines list for special circumstances, emergencies and ensuring availability. In practice, he said, every drug is essential for some patient somewhere.

The government, he said, had argued that it was concerned only about expensive drugs. He responded by asking who would decide which medicine was expensive and which was cheap. He insisted that inexpensive medicines should remain affordable. Traders and chemists, he said, fix their profit percentages individually, and each seller handles both cheap and costly drugs, so overall earnings come from the whole stock. Price regulation, therefore, should be more logical and uniform, and the essential versus non-essential classification was largely arbitrary, he argued.

The court, he said, offered two significant suggestions. One was to consider applying the MRP system at the manufacturing stage. The other was to create a website or mobile application that clearly displays the margins taken by manufacturers, distributors, stockists and retailers. Such a platform should also show whether a drug is essential or non-essential and whether it is patented or generic. He said the court had listened to these points and considered them.

He expressed hope that the court had examined the matter from a public health and welfare standpoint, not just a commercial one. He also said that without profit potential in healthcare, companies and investors would not invest in such large numbers.

He noted that companies from Japan, Korea and other countries were investing in India's health sector, and hospitals were being acquired, indicating strong profit expectations in the sector.

On generic drugs, he clarified that he was not against them. As doctors, they backed generic medicines, but certain flaws needed fixing. The first flaw, he said, arises when too many companies are permitted to make the same generic drug. This often leads to unethical competition to push sales, with the product offering higher margins receiving greater promotion.